Evidence map›Paper›PMID 40973605›Full record

ArticleThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2026

Accelerated Cognitive Decline in Late Life Depression: The Role of Amyloid-β, Cortico-Limbic Volume, and White Matter Hyperintensities.

Emma Rhodes, Philip S Insel, Michelle Kassel, Maria Kryza-Lacombe, Meryl A Butters, David Bickford, Duygu Tosun, Ruth Morin, Paul Aisen, Howie Rosen and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Emma RhodesMental Illness Research Education and Clinical Centers (ER, MK, MKL), Veterans Administration Medical Center, San Francisco, CA; Department of Neurology, Frontotemporal Degeneration Center (ER), University of Pennsylvania, Philadelphia, PA.
Philip S InselDepartment of Psychiatry and Behavioral Sciences (PSI, MK, DB, MWW, CN, RSM), University of California San Francisco, San Francisco, CA.
Michelle KasselMental Illness Research Education and Clinical Centers (ER, MK, MKL), Veterans Administration Medical Center, San Francisco, CA; Department of Psychiatry and Behavioral Sciences (PSI, MK, DB, MWW, CN, RSM), University of California San Francisco, San Francisco, CA.
Maria Kryza-LacombeMental Illness Research Education and Clinical Centers (ER, MK, MKL), Veterans Administration Medical Center, San Francisco, CA.
Meryl A ButtersDepartment of Psychiatry Western Psychiatric Hospital (MAB), University of Pittsburgh School of Medicine, Pittsburgh, PA.
David BickfordDepartment of Psychiatry and Behavioral Sciences (PSI, MK, DB, MWW, CN, RSM), University of California San Francisco, San Francisco, CA.
Duygu TosunVeterans Administration Medical Center (DT, RSM), San Francisco, CA; Department of Radiology and Biomedical Imaging (DT, MWW), University of California San Francisco, San Francisco, CA.
Ruth MorinHoag Memorial Hospital Presbyterian (RM), Newport Beach, CA.
Paul AisenDepartment of Neurology, Keck School of Medicine (PA, RR), University of Southern California, Los Angeles, CA; Keck School of Medicine (PA), Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA.
Howie RosenDepartment of Neurology, Memory and Aging Center (HR, RR), University of California, San Francisco, CA.
Rema RamanDepartment of Neurology, Keck School of Medicine (PA, RR), University of Southern California, Los Angeles, CA; Department of Neurology, Memory and Aging Center (HR, RR), University of California, San Francisco, CA.
Susan LandauNeuroscience Department, Helen Wills Neuroscience Institute (SL), University of California, Berkeley, CA.
Andrew SaykinDepartment of Radiology and Imaging Sciences, Indiana University School of Medicine (AS), Indianapolis, IN.
Arthur W TogaLaboratory of Neuro Imaging (AWT), Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Clifford R JackMayo Clinic (CRJ), Rochester, MN.
Michael W WeinerDepartment of Psychiatry and Behavioral Sciences (PSI, MK, DB, MWW, CN, RSM), University of California San Francisco, San Francisco, CA; Department of Radiology and Biomedical Imaging (DT, MWW), University of California San Francisco, San Francisco, CA.
Craig NelsonDepartment of Psychiatry and Behavioral Sciences (PSI, MK, DB, MWW, CN, RSM), University of California San Francisco, San Francisco, CA.
R Scott MackinDepartment of Psychiatry and Behavioral Sciences (PSI, MK, DB, MWW, CN, RSM), University of California San Francisco, San Francisco, CA; Veterans Administration Medical Center (DT, RSM), San Francisco, CA. Electronic address: Scott.mackin@ucsf.edu.
Alzheimer’s Disease Neuroimaging Initiative

Funding

Characterizing Cognitive Decline in Late Life Depression: The ADNI-D ProjectR01MH098062 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Robert Scott Mackin · 2013 to 2026
$9.1M
Digital monitoring of autonomic activity to detect empathy loss in behavioral variant frontotemporal dementiaK23AG083124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Emma Rhodes · 2023 to 2026
$652k
NIA NIH HHS K23 AG083124NIMH NIH HHS R01 MH098062
6 · The paper itself

Abstract

objectivesLate life depression (LLD) is associated with cognitive impairment and dementia, but studies of cognitive decline in LLD have been confounded by underlying Alzheimer's disease (AD). We evaluated longitudinal cognition in LLD against nondepressed (ND) older adults with equivalent AD risk and pathology and assessed relative contributions of clinical and neuroimaging characteristics to cognitive change.

designLongitudinal.

settingOutpatient psychiatry program.

participantsParticipants (120 LLD, 240 ND) were matched on demographics, global cognition, mild cognitive impairment diagnosis, and Amyloid-β (Aβ) positivity. MEASUREMENTS: Participants underwent genetic testing, 3T MRI, and Aβ PET at baseline, and serial neuropsychological assessment extending up to 36 months postbaseline.

resultsAfter accounting for demographics, MCI diagnosis, and AD risk and pathology, LLD showed accelerated decline on tests of global cognition, verbal memory, and attention/processing speed. Lower baseline cortico-limbic volume was associated with greater decline in global cognition, verbal memory, and attention/processing speed regardless of LLD diagnosis. Baseline Aβ positivity predicted greater decline on tests of global cognition and verbal learning and memory regardless of LLD diagnosis. White matter hyperintensity burden predicted faster decline in attention/processing speed and verbal learning in LLD. MCI diagnosis did not predict cognitive decline in either group.

conclusionsThese findings demonstrate significant cognitive decline in LLD independent of Aβ pathology and highlight the importance of identifying causal mechanisms for cortico-limbic volume abnormalities in this patient population.

Indexed as

Amyloid beta-PeptidesCerebral CortexCognitive DysfunctionDepressionLimbic SystemWhite MatterAgedAged, 80 and overAlzheimer DiseaseDisease ProgressionFemaleHumansLongitudinal StudiesMagnetic Resonance ImagingMaleNeuropsychological TestsAmyloid beta-PeptidesamyloidapolipoproteinsDepressionneuropsychology

Identifiers

PMID40973605
PMCPMC13343322

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.